Pfizer Q4 profit falls despite revenue, EBITDA growth; ₹75 dividend declared

Pfizer Ltd reported a mixed set of fourth-quarter earnings for FY26 on May 12, with revenue and operating profit rising year-on-year, although net profit declined sharply during the period.

The company posted a net profit of ₹200 crore for the quarter, down 39.6% from ₹311 crore in the corresponding period last year.

Revenue rose 6.3% to ₹629.2 crore from ₹592 crore a year ago, while EBITDA increased 3.7% to ₹236 crore compared with ₹228 crore in the year-ago quarter.

Operating margin came in at 37.5%, slightly lower than 38.4% recorded in the corresponding quarter last year.

The board of directors recommended a final dividend of ₹75 per equity share, or 750% on the face value of ₹10 each, for the financial year ended March 31, 2026. If approved by shareholders at the upcoming annual general meeting, the dividend will be paid on or after August 4, 2026. The record date for determining eligible shareholders has been fixed as July 17, 2026.

Ahead of the earnings announcement, shares of Pfizer Ltd closed over 3% lower at ₹4,728.90 on the NSE.

The latest quarter comes after Pfizer reported a strong performance in the December quarter, when revenue grew nearly 20% year-on-year and EBITDA surged over 55%, aided by improved operating leverage and healthy demand across key therapy segments. Margins had expanded sharply during that quarter on the back of stronger cost efficiencies and higher sales growth.

Also Read: Dixon Tech Q4 Results: Revenue up 2%, margin narrows but better than feared; Dividend declared

Pfizer Ltd is the Indian arm of global pharmaceutical major Pfizer and manufactures as well as markets medicines and vaccines across multiple therapeutic areas, including anti-infectives, cardiology, pain management and immunology.